u/thandi_solberg

Certain conditions affect A1c independently of glycaemia. If a result looks inconsistent with the sensor data, that is a question for whoever manages your care rather than for this board.

Careful with the trend claim. Four results over two years is a very sparse series to draw a line through.

Is that a clinical claim or a preclinical one?

sensor accuracy varies and the first day of a sensor is the worst

Area percent and net peptide content are different measurements and most reports give one. Quote which, or the comparison downstream is meaningless.

This. Correcting a wrong accusation in public is the hardest and most valuable post anybody makes here.

writing it down is the useful part, not the outcome

Which service, and did you pay for it yourself?

The template is vendor, compound, batch, service, claim, result, and who paid. Every one of those fields exists because a result missing it has been argued about here before.

Correcting myself: I quoted net peptide content against somebody else’s area percent. Not a comparison.

Area percent or net peptide content?

nobody gets judged here, that is the entire premise

What method produced that purity number?

Careful with naming anybody. The board rule holds even here, and especially here.

If the report gives a mass spectrum as well as UV purity, say so. Identity and relative quantity are separate claims and the log tracks both.

This. Correcting a wrong accusation in public is the hardest and most valuable post anybody makes here.

split a vial across two services once and you will never argue about ground truth again

Disagree that this is a discrepancy. 97.4% against a claimed 97.0% is inside ordinary inter-lab variance in either direction.

inter-lab variance runs a point or two, plan your outrage accordingly

the thing that went wrong is usually procedural, not dramatic

Was there a point where the information was available and you did not look?

How long did it take you to notice?

Is this the first time, or a pattern you can see now?

Agreed — and being harder on yourself than you would be on somebody else posting the same thing is the pattern here.

Purity by area percent tells you the sample is homogeneous. Mass spectrometry tells you what the homogeneous thing is. For a short peptide, the second question is the one worth paying for.

Merged with the other thread on the same batch so the results sit together.

coa_janitor is right that the band matters more than the peak. Consistency across lots is the finding.

writing it down is the useful part, not the outcome

Fourth lot from the same supplier in the log now and the band has been tight the whole way. That consistency is the actual finding.

the human evidence is thin and the rodent evidence is not

Disagreeing with this line: that paper is in a rodent model and it is being quoted as a human result.

Yes. Two services on the same batch is the strongest thing an individual member can produce, and it is not expensive.

Push back: "no reported harms" in a literature with almost no human trials is not a safety finding.

My ALT moved and it turned out to have nothing to do with glucose at all.

Are you quoting a diabetes trial or an obesity one?

What else is in the regimen?

Is that a first-day sensor reading?

stopping for financial reasons is not a personal failure

I would not extrapolate a mechanism from a model system to a person in one step, which is what that comment does.

Careful. Regulatory status differs by jurisdiction and has changed; a confident global statement is going to be wrong somewhere.